An evaluation of the effects and safety of Zuogui pill for treating osteoporosis: Current evidence for an ancient Chinese herbal formula.
An evaluation of the effects and safety of Zuogui pill for treating osteoporosis: Current evidence for an ancient Chinese herbal formula.
复制标题
左归丸治疗骨质疏松症的疗效和安全性评价：古方中药的现有证据
DOI：
10.1002/ptr.6908
复制
发表时间：
2021-04
期刊：
影响因子：
--
通讯作者：
Jia Y
中科院分区：
文献类型：
--
作者：
Li J;Sun K;Qi B;Feng G;Wang W;Sun Q;Zheng C;Wei X;Jia Y
本研究的目的是系统评价中药左桂丸治疗骨质疏松症的现有证据。在六个电子数据库中进行了系统的文献检索。作者独立成对地提取数据并评估偏倚风险。初步共纳入221篇文献，其中纳入12项相关研究。主要观察指标是不同部位的骨折发生率和骨密度。骨代谢指标、临床症状、生活质量和不良事件或药物不良反应（adr）是次要结局。结果显示，ZGP联合抗骨质疏松药物可显著增加腰椎、沃德区和全髋关节的骨密度。在改善骨代谢的标志物方面，ZGP加常规药物显著提高了碱性磷酸酶、骨Gla蛋白、骨碱性磷酸酶和酒石酸盐抗性酸性磷酸酶的水平。联合治疗组出现胃肠道不适、头晕、乏力等症状。虽然结果表明ZGP是骨质疏松症的潜在候选者，但证据仍然不足。进一步严格设计和更大样本量的高质量试验有必要验证当前的结论。
The aim of this study is to systematically evaluate existing evidence of the Chinese herbal formula, Zuogui pill (ZGP), for the treatment of osteoporosis. A systematic literature search was performed in six electronic databases. The authors independently extracted data in pairs and evaluated the risk of bias. A total of 221 articles were identified initially, of which 12 relevant studies were enrolled. The primary outcome was fracture incidence and bone mineral density (BMD) at different sites. Bone metabolism markers, clinical symptoms, quality of life, and adverse events or adverse drug reactions (ADRs) were secondary outcomes. The results showed that ZGP, combined with anti‐osteoporosis drugs, significantly increased BMD at the lumbar spine, Ward's area, and total hip. In terms of markers for improved bone metabolism, ZGP plus conventional drugs dramatically improved the levels of alkaline phosphatase, bone Gla protein, bone alkaline phosphatase, and tartrate‐resistant acid phosphatase. Gastrointestinal discomfort, dizziness, and fatigue were found in the combined therapy group. Although the results indicate that ZGP is a potential candidate for osteoporosis, evidence remains insufficient. Further rigorously designed and high‐quality trials with a larger sample size are warranted to verify the current conclusions.
登录
查看更多内容
影响因子：
2.6
作者：
Liu Mei-jie;Li Yan;Ju Da-hong
通讯作者：
Ju Da-hong
DOI：
10.4084/mjhid.2010.005
发表时间：
2010-04-20
影响因子：
3.2
作者：
Khalafallah A;Maiwald M;Cox A;Burns D;Bates G;Hannan T;Seaton D;Fernandopulle B;Meagher D;Brain T
通讯作者：
Brain T
影响因子：
105.7
作者：
Higgins, JPT;Thompson, SG;Altman, DG
通讯作者：
Altman, DG
影响因子：
4.5
作者：
Chen P;Li Z;Hu Y
通讯作者：
Hu Y
影响因子：
6.7
作者：
Aspray, Terry J.;Bowring, Claire;Francis, Roger M.
通讯作者：
Francis, Roger M.